Protect your pharma franchise from parallel trade, counterfeit pills and substandard drugs
Brand-protection teams in pharma face a dual threat: genuine opioids siphoned to lower-priced markets and counterfeit fentanyl-laced tablets that endanger patients. The financial and safety stakes are soaring.
We model up to $952M in annual loss for a typical branded opioid franchise.
The model captures three primary pathways that erode revenue and endanger lives. First, genuine opioid product is sourced in lower-priced regions such as Eastern Europe, Turkey and parts of LATAM, then diverted by parallel-import wholesalers into higher-priced Western markets, undercutting margins. Second, counterfeit pressed pills bearing the brand’s trade dress appear on US and EU street markets, often laced with illicit fentanyl, exposing hundreds of thousands of patients to fatal risk. Third, substandard or falsified product circulates through informal pharmacies in low- and middle-income countries, creating additional safety liabilities.
Why is the pharmaceutical franchise sector uniquely vulnerable?
Because opioid therapies are high-volume, high-margin products that are regulated differently across regions, making price differentials and supply-chain complexity a perfect breeding ground for parallel trade and counterfeit infiltration.
How does Eonpass address these risks with its three pillars?
Eonpass combines (1) a global connection graph that maps legitimate and illicit distributors, (2) AI-driven OSINT that surfaces counterfeit manufacturing signatures, and (3) collaborative IP case management that lets your team coordinate rapid response across jurisdictions.
What does an investigation look like for a pharma brand?
An investigation starts with the graph flagging suspicious volume shifts, then overlays trade-data and private sources to pinpoint the actors moving genuine product into unauthorized channels, and finally triggers alerts for counterfeit pill clusters so you can initiate recall, litigation or law-enforcement engagement.
See the impact model on your numbers
We maintain a quantitative model behind these headline figures. It accounts for parallel-trade economics, channel mix, brand damage, and (where relevant) patient-safety exposure. The most useful way to use it is together: brand-protection, legal, and finance teams tune the assumptions for your portfolio, and we walk through what changes. The conversation usually takes 30 minutes and produces a one-page summary you can take to a board or budget review.
Request a guided walkthrough →
Frequently asked questions
How does parallel import affect my brand’s margin?
Parallel imports sell the same genuine product at a discount of about 30% compared with authorized Western prices, eroding margins and triggering MAP/tender price pressure.
Can Eonpass help quantify patient safety exposure?
Yes, the platform estimates the number of patients exposed to counterfeit or substandard opioids and translates that exposure into potential litigation and liability costs.
What data sources feed the Eonpass model?
The model draws on global trade data, customs filings, pharmacy sales records, law-enforcement alerts and proprietary OSINT feeds to build a comprehensive view of diversion corridors.
Talk to us
Ready to protect your franchise from multi-billion-dollar losses and safeguard patients? Get started now at https://eonpass.com/get-started.